US2015374271A1PendingUtilityA1

Analyte monitoring system and method

Assignee: ABBOTT DIABETES CARE INCPriority: Jun 7, 2006Filed: Sep 4, 2015Published: Dec 31, 2015
Est. expiryJun 7, 2026(expired)· nominal 20-yr term from priority
A61B 5/7282A61M 5/1723A61B 5/14865A61B 5/14532A61B 5/076A61B 5/1495A61B 2562/125A61M 2005/1726A61B 5/746C12Q 1/006A61B 5/14546G01N 33/48792A61B 5/1486
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Devices and methods for monitoring an analyte are provided. Embodiments include continuous analyte sensors having a high degree of accuracy.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An in vivo analyte monitoring method, comprising:
 positioning an electrochemical analyte sensor under a skin surface of a human and in fluid contact with a bodily fluid for a duration of sensor life ranging from 1 day to 30 days, wherein the electrochemical analyte sensor is adapted to sample an analyte level in the bodily fluid;   wirelessly transmitting a data signal from a transmitter coupled with the electrochemical analyte sensor to a receiver device, the data signal corresponding to an analyte level sampled by the electrochemical analyte sensor;   determining, at the receiver device, the analyte level using the data signal received from the electrochemical analyte sensor; and   displaying, on a display of the receiver device, the analyte level, wherein the analyte level is changing at a rate between −2 mg/dl/min to 2 mg/dl/min and wherein the analyte level is displayed without confirming the accuracy level of the received data signal using an adjunctive measurement.   
     
     
         2 . The method of  claim 1 , wherein the electrochemical analyte sensor is calibrated with factory-only calibration. 
     
     
         3 . The method of  claim 1 , wherein the adjunctive measurement includes a blood glucose measurement. 
     
     
         4 . The method of  claim 1 , further comprising generating an alarm or an alert, at the receiver device, when the analyte level is at or near a threshold level. 
     
     
         5 . The method of  claim 4 , wherein the threshold level is indicative of hypoglycemia. 
     
     
         6 . The method of  claim 4 , wherein the threshold level is indicative of hyperglycemia. 
     
     
         7 . The method of  claim 1 , further comprising:
 receiving, by an insulin infusion device, the determined analyte level from the receiver device; and   automatically administering insulin to the human with the insulin infusion device based on the analyte level received from the receiver device.   
     
     
         8 . The method of  claim 1 , wherein an insulin infusion device is integrated with the receiver device, the method comprising automatically administering insulin to the human with the insulin infusion device based on the analyte level determined by the receiver device. 
     
     
         9 . The method of  claim 1 , wherein the electrochemical analyte sensor comprises a working electrode that comprises an analyte-responsive enzyme and a mediator. 
     
     
         10 . The method of  claim 9 , wherein a polymer is chemically bonded to a functional group on a surface of the working electrode. 
     
     
         11 . An in vivo analyte monitoring system, comprising:
 an electrochemical analyte sensor adapted to be positioned under a skin surface of a human and in fluid contact with a bodily fluid for a duration of sensor life ranging from 1 day to 30 days, wherein the electrochemical analyte sensor is adapted to sample an analyte level in the bodily fluid;   a wireless transmitter coupled with the electrochemical analyte sensor and adapted to transmit a data signal corresponding to an analyte level sampled by the electrochemical analyte sensor;   a receiver device comprising a display, wherein the receiver device is adapted to determine the analyte level using the data signal received from the electrochemical analyte sensor and display the analyte level when changing at a rate between −2 mg/dl/min to 2 mg/dl/min without confirmation of the accuracy level of the received data signal with an adjunctive measurement.   
     
     
         12 . The system of  claim 11 , wherein the receiver device is operable with the electrochemical analyte sensor calibrated with factory-only calibration. 
     
     
         13 . The system of  claim 11 , wherein the adjunctive measurement includes a blood glucose measurement. 
     
     
         14 . The system of  claim 11 , wherein the receiver device generates an alarm or an alert when the analyte level is at or near a threshold level. 
     
     
         15 . The system of  claim 14 , wherein the threshold level is indicative of hypoglycemia. 
     
     
         16 . The system of  claim 14 , wherein the threshold level is indicative of hyperglycemia. 
     
     
         17 . The system of  claim 11 , further comprising an insulin infusion device adapted to receive the determined analyte level from the receiver device and automatically administer insulin to the human based on the analyte level received from the receiver device. 
     
     
         18 . The system of  claim 11 , further comprising an insulin infusion device integrated with the receiver device, the insulin infusion device adapted to automatically administer insulin to the human based on the analyte level determined by the receiver device. 
     
     
         19 . The system of  claim 11 , wherein the electrochemical analyte sensor comprises a working electrode that comprises an analyte-responsive enzyme and a mediator. 
     
     
         20 . The system of  claim 19 , wherein a polymer is chemically bonded to a functional group on a surface of the working electrode.

Join the waitlist — get patent alerts

Track US2015374271A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.